Globus Medical Inc GMED
We take great care to ensure that the data presented and summarized in this overview for GLOBUS MEDICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMED
View all-
Vanguard Group Inc Valley Forge, PA10.9MShares$861 Million0.02% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$819 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X06.61MShares$524 Million0.29% of portfolio
-
State Street Corp Boston, MA3.59MShares$285 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.8MShares$222 Million0.02% of portfolio
-
Burgundy Asset Management Ltd. Toronto, A62.62MShares$207 Million2.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.57MShares$204 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA2.5MShares$198 Million0.04% of portfolio
-
Sculptor Capital LP New York, NY2.08MShares$165 Million5.03% of portfolio
-
Geode Capital Management, LLC Boston, MA1.9MShares$150 Million0.01% of portfolio
Latest Institutional Activity in GMED
Top Purchases
Top Sells
About GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Insider Transactions at GMED
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 28
2025
|
Ann D Rhoads |
SELL
Open market or private sale
|
Direct |
7,500
-17.49%
|
$585,000
$78.68 P/Share
|
Jan 10
2025
|
Keith W Pfeil COO, CFO |
SELL
Open market or private sale
|
Direct |
14,167
-94.12%
|
$1,246,696
$88.67 P/Share
|
Jan 10
2025
|
Keith W Pfeil COO, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,167
+43.52%
|
$722,517
$51.46 P/Share
|
Dec 02
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$217,500
$87.0 P/Share
|
Dec 02
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$60,000
$24.21 P/Share
|
Nov 22
2024
|
David D Davidar |
SELL
Open market or private sale
|
Indirect |
6,746
-3.91%
|
$573,410
$85.0 P/Share
|
Nov 22
2024
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
6,766
-1.29%
|
$575,110
$85.0 P/Share
|
Nov 22
2024
|
Dan Lemaitre |
SELL
Open market or private sale
|
Direct |
1,097
-100.0%
|
$93,245
$85.02 P/Share
|
Nov 22
2024
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
1,097
+50.0%
|
$71,305
$65.05 P/Share
|
Nov 21
2024
|
David D Davidar |
SELL
Open market or private sale
|
Indirect |
13,254
-7.13%
|
$1,126,590
$85.0 P/Share
|
Nov 21
2024
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
13,234
-2.47%
|
$1,124,890
$85.0 P/Share
|
Nov 21
2024
|
Dan Lemaitre |
SELL
Open market or private sale
|
Direct |
13,278
-100.0%
|
$1,128,630
$85.0 P/Share
|
Nov 21
2024
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
13,278
+50.0%
|
$863,070
$65.05 P/Share
|
Nov 21
2024
|
Daniel T Scavilla President, CEO |
SELL
Open market or private sale
|
Direct |
130,000
-100.0%
|
$11,050,000
$85.0 P/Share
|
Nov 21
2024
|
Daniel T Scavilla President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+44.05%
|
$5,590,000
$43.68 P/Share
|
Nov 15
2024
|
David C Paul Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
26,042
+50.0%
|
$625,008
$24.1 P/Share
|
Nov 06
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
5,000
-75.0%
|
$405,000
$81.01 P/Share
|
Nov 06
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$120,000
$24.21 P/Share
|
Nov 06
2024
|
Daniel T Scavilla President, CEO |
SELL
Open market or private sale
|
Direct |
60,000
-100.0%
|
$4,800,000
$80.02 P/Share
|
Nov 06
2024
|
Daniel T Scavilla President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+41.67%
|
$2,100,000
$35.02 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 372K shares |
---|
Open market or private sale | 466K shares |
---|